U.S. Markets closed

Navidea Biopharmaceuticals, Inc. (NAVB)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.56000.0000 (0.00%)
At close: 4:00PM EDT
1.6300 +0.06 (3.82%)
After hours: 07:37PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.5600
Open1.5600
Bid1.5000 x 800
Ask1.6500 x 1000
Day's Range1.5500 - 1.6299
52 Week Range1.4600 - 3.1500
Volume23,897
Avg. Volume71,100
Market Cap45.28M
Beta (5Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)-0.4520
Earnings DateMay 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
  • Zacks

    Navidea Biopharma (NAVB) Reports Q2 Loss, Misses Revenue Estimates

    Navidea (NAVB) delivered earnings and revenue surprises of 0.00% and -56.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results

    DUBLIN, Ohio, August 11, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended June 30, 2021.

  • Business Wire

    Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update

    DUBLIN, Ohio, August 04, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, August 11, 2021 at 5:00 p.m. (EDT) to discuss financial results and corporate developments for the second quarter ended June 30, 2021.